Eliana Clark - Jan 2, 2025 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Technical Officer
Signature
James Basta, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Jan 2, 2025
Transactions value $
-$97,089
Form type
4
Date filed
1/6/2025, 04:16 PM
Previous filing
Jul 3, 2024
Next filing
Mar 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Sale -$6.69K -556 -0.77% $12.03 71.5K Jan 2, 2025 Direct F1
transaction NTLA Common Stock Sale -$90.4K -7.42K -10.38% $12.18 64K Jan 3, 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of 556 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2024.
F2 Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person.